Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.drup.2020.100719 http://scihub22266oqcxt.onion/10.1016/j.drup.2020.100719 32717568!7362818!32717568     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Drug+Resist+Updat 2020 ; 53 (ä): 100719 Nephropedia Template TP {{tp|p=32717568|t=2020. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy |pdf=|usr=}}{{32717568}} gab.com Text FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy JO: Drug Resist Updat http://www.kidney.de/pget.php?&tw=1&pmid=32717568 #FOAvip In December 2019, a novel SARS-CoV-2 coronavirus emerged, causing an outbreak of life-threatening pneumonia in the Hubei province, China, and has now spread worldwide, causing a pandemic. The urgent need to control the disease, combined with the lack of specific and effective treatment modalities, call for the use of FDA-approved agents that have shown efficacy against similar pathogens. Chloroquine, remdesivir, lopinavir/ritonavir or ribavirin have all been successful in inhibiting SARS-CoV-2 in vitro. The initial results of a number of clinical trials involving various protocols of administration of chloroquine or hydroxychloroquine mostly point towards their beneficial effect. However, they may not be effective in cases with persistently high viremia, while results on ivermectin (another antiparasitic agent) are not yet available. Interestingly, azithromycin, a macrolide antibiotic in combination with hydroxychloroquine, might yield clinical benefit as an adjunctive. The results of clinical trials point to the potential clinical efficacy of antivirals, especially remdesivir (GS-5734), lopinavir/ritonavir, and favipiravir. Other therapeutic options that are being explored involve meplazumab, tocilizumab, and interferon type 1. We discuss a number of other drugs that are currently in clinical trials, whose results are not yet available, and in various instances we enrich such efficacy analysis by invoking historic data on the treatment of SARS, MERS, influenza, or in vitro studies. Meanwhile, scientists worldwide are seeking to discover novel drugs that take advantage of the molecular structure of the virus, its intracellular life cycle that probably elucidates unfolded-protein response, as well as its mechanism of surface binding and cell invasion, like angiotensin converting enzymes-, HR1, and metalloproteinase inhibitors. Twit Text FOAVip FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy ????Drug Resist Updat http://www.kidney.de/pget.php?&tw=1&pmid=32717568 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32717568 #FOAvip English Wikipedia <ref>{{Cite pmid|32717568}}</ref> FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy #MMPMID32717568 Drozdzal S; Rosik J; Lechowicz K; Machaj F; Kotfis K; Ghavami S; Los MJ Drug Resist Updat 2020[Dec]; 53 (ä): 100719 PMID32717568show ga In December 2019, a novel SARS-CoV-2 coronavirus emerged, causing an outbreak of life-threatening pneumonia in the Hubei province, China, and has now spread worldwide, causing a pandemic. The urgent need to control the disease, combined with the lack of specific and effective treatment modalities, call for the use of FDA-approved agents that have shown efficacy against similar pathogens. Chloroquine, remdesivir, lopinavir/ritonavir or ribavirin have all been successful in inhibiting SARS-CoV-2 in vitro. The initial results of a number of clinical trials involving various protocols of administration of chloroquine or hydroxychloroquine mostly point towards their beneficial effect. However, they may not be effective in cases with persistently high viremia, while results on ivermectin (another antiparasitic agent) are not yet available. Interestingly, azithromycin, a macrolide antibiotic in combination with hydroxychloroquine, might yield clinical benefit as an adjunctive. The results of clinical trials point to the potential clinical efficacy of antivirals, especially remdesivir (GS-5734), lopinavir/ritonavir, and favipiravir. Other therapeutic options that are being explored involve meplazumab, tocilizumab, and interferon type 1. We discuss a number of other drugs that are currently in clinical trials, whose results are not yet available, and in various instances we enrich such efficacy analysis by invoking historic data on the treatment of SARS, MERS, influenza, or in vitro studies. Meanwhile, scientists worldwide are seeking to discover novel drugs that take advantage of the molecular structure of the virus, its intracellular life cycle that probably elucidates unfolded-protein response, as well as its mechanism of surface binding and cell invasion, like angiotensin converting enzymes-, HR1, and metalloproteinase inhibitors. |*COVID-19 Drug Treatment[MESH] |Animals[MESH] |Anti-Bacterial Agents/administration & dosage/metabolism[MESH] |Antibodies, Monoclonal, Humanized/administration & dosage/metabolism[MESH] |Antimalarials/administration & dosage/metabolism[MESH] |Antiviral Agents/*administration & dosage/metabolism[MESH] |COVID-19/metabolism[MESH] |Clinical Trials as Topic/methods[MESH] |Cytochrome P-450 CYP3A Inhibitors/administration & dosage/metabolism[MESH] |Drug Approval/*methods[MESH] |Drug Therapy, Combination[MESH] |Humans[MESH] |Hydroxychloroquine/administration & dosage/metabolism[MESH] |SARS-CoV-2/*drug effects/metabolism[MESH]FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 ((epmc).pdf DeepDyve Pubget Overpricing